A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...
Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment. An international ...
As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious bacterial infection that is resistant to most antibiotic treatments. Healing is possible but severe infections may become chronic or ...
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of ...
Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product ...
Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that causes an infection that may be resistant to many antibiotics. There are precautions you can take to avoid contracting ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotech company specializing in precision phage therapy for the treatment of resistant and/or complicated ...
LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results